| ASX Limited (ASX) ORDINARY FULLY PAID |
Financials |
$10,148 |
Webcast Details and Key Dates for 2025 Full-Year Results
|
29 Jul 2025 9:57AM |
$70.210 |
$52.230 |
fallen by
25.61%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$62 |
Notice under Section 708A(5)(e) of the Corporations Act
|
29 Jul 2025 9:55AM |
$0.240 |
$0.120 |
fallen by
50%
|
|
| Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID |
Health Care |
$78 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 9:55AM |
$0.022 |
$0.022 |
fallen by
0%
|
|
RAD - Price-sensitive ASX Announcement
Full Release
Key Points
- Radiopharm Theranostics Limited (RAD) provided an update on its activities for the quarter ended 31 March 2024.
- The company made significant progress across its clinical development pipeline, including Phase I and Phase II trials for its radiopharmaceutical products.
- RAD received regulatory and ethics approvals for its Phase I clinical trial of RAD 301 in the US for treatment of patients with advanced solid tumors.
- The company's Phase I trial of RAD 204 (Nano-mAbs) for HER2-positive breast cancer commenced recruitment.
- RAD reported the initiation of a preclinical research collaboration with leading academic and clinical partners.
- A collaboration with MD Anderson Cancer Center for the development of novel radiopharmaceuticals was highlighted.
- RAD continued to advance its global intellectual property portfolio, filing new patents.
- The company reported operating cash outflows of approximately $5.2 million during the quarter.
- RAD had a cash balance of $26.9 million at the end of the reporting period, positioning it well to fund ongoing clinical trials and research.
- No payments were made to related parties or their associates other than director fees and reimbursement of expenses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prescient Therapeutics Limited (PTX) ORDINARY FULLY PAID |
Health Care |
$67 |
Prescient announces results of SPP & Launches Placement
|
29 Jul 2025 9:54AM |
$0.045 |
$0.064 |
risen by
42.22%
|
|
PTX - Price-sensitive ASX Announcement
Full Release
Key Points
- Prescient Therapeutics Limited completed a Share Purchase Plan (SPP) raising approximately $2.7 million.
- A new placement is launched aiming to raise a further $5 million at the same issue price as the SPP.
- Funds raised will support the advancement of the OmniCAR and CellPryme cancer therapy platforms.
- The capital will also be used for general working capital requirements.
- Shareholders were thanked for their continued support.
- The company outlined its strategy to progress both financial and research objectives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resolution Minerals Ltd (RML) ORDINARY FULLY PAID |
Materials |
$83 |
Resolution to Pursue NASDAQ Listing
|
29 Jul 2025 9:53AM |
$0.079 |
$0.041 |
fallen by
48.10%
|
|
RML - Price-sensitive ASX Announcement
Full Release
Key Points
- Resolution Minerals Ltd intends to pursue a listing on the NASDAQ stock exchange.
- The decision aims to access deeper capital markets and attract North American investors.
- NASDAQ is viewed as providing greater access to capital for mineral exploration companies.
- The company will maintain its existing ASX listing alongside the proposed NASDAQ listing.
- The dual listing is expected to increase visibility, liquidity, and access to funding.
- The process involves meeting NASDAQ's listing requirements and regulatory approvals.
- Shareholder engagement and communication remain a priority during the transition.
- The move supports Resolution Minerals' strategy for growth and exploration activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Diatreme Resources Limited (DRX) ORDINARY FULLY PAID |
Materials |
$85 |
Diatreme signs negotiation protocol with Gulaal People
|
29 Jul 2025 9:52AM |
$0.018 |
$0.017 |
fallen by
5.56%
|
|
DRX - Price-sensitive ASX Announcement
Full Release
Key Points
- Diatreme Resources Limited has signed a negotiation protocol with the Gulaal People.
- The Gulaal People are the native title claimants for the Cape Bedford Silica Sand Project area.
- The protocol provides a framework for respectful engagement and negotiation.
- The agreement aims to support both project advancement and Gulaal People interests.
- This milestone enhances Diatreme’s commitment to working collaboratively with traditional owners.
- The negotiation process will address cultural, social, and economic considerations.
- Formal agreement is the intended outcome of the protocol to enable project development.
- Diatreme recognises the importance of ensuring free, prior, and informed consent from traditional owners.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Activex Limited (AIV) ORDINARY FULLY PAID |
Materials |
$6 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Jul 2025 9:52AM |
$0.016 |
$0.022 |
risen by
37.50%
|
|
AIV - Price-sensitive ASX Announcement
Full Release
Key Points
- Activex Limited (AIV) released its Quarterly Activities Report and Appendix 5B Cash Flow Report for the quarter ended 31 March 2024.
- The company made significant progress on the Florence Lake and Horseshoe West nickel exploration projects in Western Australia.
- Florence Lake drilling identified high-grade nickel sulphide, with notable intersections and successful downhole electromagnetic surveys completed.
- Horseshoe West drilling program commenced, with initial results confirming key geological features and encouraging follow-up exploration.
- Corporate activities included completion of a share placement raising $1.3 million before costs, and the appointment of a new Non-Executive Director.
- Cash outflows were primarily related to exploration and evaluation activities, with $1.1 million spent during the quarter.
- As of 31 March 2024, Activex reported a cash balance of $2.6 million.
- No mining production or development activities occurred during the quarter.
- The Appendix 5B report detailed exploration, staff, administration, and fundraising expenditure, with no payments to related parties during the reporting period.
- The company remains focused on advancing its nickel projects and maintaining a strong liquidity position for ongoing exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sequoia Financial Group Ltd (SEQ) ORDINARY FULLY PAID |
Financials |
$33 |
Pause in Trading
|
29 Jul 2025 9:51AM |
$0.240 |
$0.270 |
risen by
12.50%
|
|
SEQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Sequoia Financial Group Ltd requested a trading halt on its securities.
- The trading halt is effective from 3 June 2024.
- The pause is pending an announcement about a material transaction.
- The halt may last until the announcement or until 5 June 2024.
- The company is not aware of any reason why the trading halt should not be granted.
- No additional market-sensitive information is being withheld.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$644 |
Geoff Wilson Appendix 3Y
|
29 Jul 2025 9:50AM |
$1.550 |
$1.605 |
risen by
3.55%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$62 |
Application for quotation of securities - ATX
|
29 Jul 2025 9:50AM |
$0.240 |
$0.120 |
fallen by
50%
|
|
| Liontown Limited (LTR) ORDINARY FULLY PAID |
Materials |
$6,311 |
June 2025 Quarter Presentation
|
29 Jul 2025 9:49AM |
$0.865 |
$1.985 |
risen by
129.48%
|
|
LTR - Price-sensitive ASX Announcement
Full Release
Key Points
- Produced over 294,000 dmt of spodumene concentrate in FY25.
- Achieved A$112M in cost savings and deferrals, exceeding target.
- Maintained a strong cash balance of A$156M as of June 2025.
- Initiated underground production, with full transition planned by Q3 FY26.
- Aimed for a 70% lithia recovery target by Q3 FY26.
- Adapted to a 36% fall in spodumene prices over 12 months.
- Secured A$300M debt facility from Ford and US$250M convertible note from LG Energy Solution.
- Planned for scalable operations, with focus on low-cost production from FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Liontown Limited (LTR) ORDINARY FULLY PAID |
Materials |
$6,311 |
June 2025 Quarter Presentation
|
29 Jul 2025 9:49AM |
$0.865 |
$1.985 |
risen by
129.48%
|
|
LTR - Price-sensitive ASX Announcement
Full Release
Key Points
- Commencement of underground production on schedule.
- Robust cash balance of A$156M at 30 June 2025.
- A$112M in cost savings and deferrals achieved in FY25.
- Transition to 100% underground production by Q3 FY26 planned.
- 70% lithia recovery target by Q3 FY26 remains unchanged.
- Over 294,000 dmt concentrate produced in FY25.
- Strategic focus on optimizing mining and processing schedules.
- Deployment of technology to improve plant performance.
- Preparation for low-cost, scalable operations expected from FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$31 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 9:49AM |
$0.018 |
$0.038 |
risen by
111.11%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Atomo Diagnostics Limited provided a detailed update for the quarter ending 31 December 2023.
- The AT1 HIV Self-Test remains a core focus, with advances in regulatory submissions and market launches, especially in Europe and Australia.
- The company engaged in partnership discussions and collaborations to expand product reach and access.
- Operational highlights include notable supply agreements and new distribution partnerships.
- Research and development activities are ongoing, with attention to product pipeline and innovation.
- Financially, Atomo reported receipts from customers, operating costs, and overall cash position in the Appendix 4C.
- The company continues to seek opportunities for market expansion and sustained financial performance.
- The report demonstrates Atomo's commitment to regulatory compliance, commercial growth, and maintaining adequate funding for its operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Unico Silver Limited (USL) ORDINARY FULLY PAID |
Materials |
$560 |
Former De Grey CFO to be appointed to Unico Board
|
29 Jul 2025 9:48AM |
$0.440 |
$0.890 |
risen by
102.27%
|
|
| Eureka Group Holdings Limited (EGH) ORDINARY FULLY PAID |
Real Estate |
$220 |
Change in substantial holding
|
29 Jul 2025 9:48AM |
$0.560 |
$0.515 |
fallen by
8.04%
|
|
| Rincon Resources Limited (RCR) ORDINARY FULLY PAID |
Materials |
$5 |
Dispatch of Prospectus
|
29 Jul 2025 9:47AM |
$0.014 |
$0.016 |
risen by
14.29%
|
|
| Spenda Limited (SPX) ORDINARY FULLY PAID |
Information Technology |
$16 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 9:47AM |
$0.007 |
$0.003 |
fallen by
57.14%
|
|
SPX - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarter ending 31 December 2023 focused on enterprise sales and merchant growth.
- Record merchant revenue achieved in the quarter.
- Completed acquisition of EonX Services Pty Ltd.
- Formed partnerships with RSM Australia and Touchpoint Group.
- Expanded customer base and transaction volume.
- Continued integration of end-to-end payments and lending solutions.
- Reported increased receipts from customers compared to previous quarters.
- Outlined cash outflows and maintained sufficient cash reserves.
- Described ongoing funding activities and planned capital management.
- Highlighted anticipated growth opportunities and strategic objectives for future quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Manhattan Gold Corporation Limited (MHC) ORDINARY FULLY PAID |
Materials |
$13 |
Proposed issue of securities - MHC
|
29 Jul 2025 9:46AM |
$0.024 |
$0.024 |
fallen by
0%
|
|
| Tabcorp Holdings Limited (TAH) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,404 |
Ceasing as a substantial holder - Aware Super
|
29 Jul 2025 9:46AM |
$0.765 |
$1.050 |
risen by
37.25%
|
|
| Manhattan Gold Corporation Limited (MHC) ORDINARY FULLY PAID |
Materials |
$13 |
Proposed issue of securities - MHC
|
29 Jul 2025 9:46AM |
$0.024 |
$0.024 |
fallen by
0%
|
|
| Manhattan Gold Corporation Limited (MHC) ORDINARY FULLY PAID |
Materials |
$13 |
$2.2 Million Placement to Advance Hook Lake Project
|
29 Jul 2025 9:45AM |
$0.024 |
$0.024 |
fallen by
0%
|
|
MHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Manhattan Corporation Limited (ASX: MHC) successfully raises $2.2 million via a placement to advance the Hook Lake Uranium Project.
- The Hook Lake Project is 100% owned by MHC and located in the Athabasca Basin, Canada, a region renowned for high-grade uranium resources.
- The placement received strong support from both new and existing institutional and sophisticated investors.
- Funds will be used for further drilling, follow-up on uranium discoveries, geophysical surveys, and expanding exploration targets.
- The technical team is experienced in uranium exploration and development, underpinning the project’s potential.
- Evolution Capital acted as Lead Manager for the placement.
- The placement is intended to accelerate exploration and unlock further value from the Hook Lake Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Rare Earths Limited (AR3) ORDINARY FULLY PAID |
Materials |
$39 |
Koppamurra metallurgical test work progressing well
|
29 Jul 2025 9:45AM |
$0.115 |
$0.155 |
risen by
34.78%
|
|
AR3 - Price-sensitive ASX Announcement
Full Release
Key Points
- Metallurgical test work at Koppamurra is progressing well.
- Leaching and beneficiation trials indicate conventional processing methods are suitable.
- Test outcomes support low-cost and sustainable extraction of rare earth elements.
- Focus on optimising recoveries and minimising environmental impact.
- Results will inform the forthcoming scoping study.
- Work underpins ongoing resource expansion and project development at Koppamurra.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anson Resources Limited (ASN) ORDINARY FULLY PAID |
Materials |
$97 |
Quarterly Activities and Cashflow Report
|
29 Jul 2025 9:44AM |
$0.105 |
$0.060 |
fallen by
42.86%
|
|
ASN - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of a Definitive Feasibility Study (DFS) for the Paradox Lithium Project Western Strategy.
- Progress in permitting and funding activities for the Paradox Lithium Project.
- Advancement of the Green River Lithium Project with permitting and drilling preparations.
- Continued exploration and development of base and precious metals projects in Western Australia.
- Significant quarterly capital expenditure focused on project development and exploration.
- Strong closing cash position at the end of the quarter.
- Strategic activities aimed at securing project financing and offtake agreements.
- Ongoing community and stakeholder engagement.
- Quarterly cashflow report detailing operating, investing, and financing activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strategic Energy Resources Limited (SER) ORDINARY FULLY PAID |
Materials |
$13 |
Trading Halt
|
29 Jul 2025 9:43AM |
$0.007 |
$0.012 |
risen by
71.43%
|
|
SER - Price-sensitive ASX Announcement
Full Release
Key Points
- Strategic Energy Resources Limited requested a trading halt on the ASX.
- The halt commenced on 4 April 2023 and will remain until the company makes a capital raising announcement or until 6 April 2023.
- The trading halt was requested under ASX Listing Rule 17.1.
- The purpose of the halt is to facilitate an orderly market while the company completes preparations for its capital raising announcement.
- Trading in SER securities will resume once the relevant announcement is made.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bathurst Resources Limited (BRL) ORDINARY FULLY PAID |
Materials |
$150 |
June 2025 Quarterly Report
|
29 Jul 2025 9:42AM |
$0.835 |
$0.625 |
fallen by
25.15%
|
|
BRL - Price-sensitive ASX Announcement
Full Release
Key Points
- Reports on production and sales volumes for the June 2025 quarter.
- Provides financial results including revenue and expenditure breakdowns.
- Details operational updates and project developments at key mining sites.
- Addresses market conditions, demand, and commodity pricing for coal.
- Highlights environmental, health, and safety performance metrics.
- Updates on exploration activities and resource development.
- Discusses regulatory matters and compliance relevant to operations.
- Outlines corporate strategies aimed at improving efficiency and growth.
- Describes measures taken for cost control and operational optimization.
- Emphasizes a continued focus on sustainability and shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
